192 related articles for article (PubMed ID: 29433143)
21. 1,3-Thiazole Derivatives as a Promising Scaffold in Medicinal Chemistry: A Recent Overview.
Kushwaha P; Pandey S
Antiinflamm Antiallergy Agents Med Chem; 2023; 22(3):133-163. PubMed ID: 37997807
[TBL] [Abstract][Full Text] [Related]
22. Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.
Musumeci F; Sanna M; Greco C; Giacchello I; Fallacara AL; Amato R; Schenone S
Expert Opin Ther Pat; 2017 Dec; 27(12):1305-1318. PubMed ID: 28705083
[TBL] [Abstract][Full Text] [Related]
23. Pyrrolopyrimidine derivatives and purine analogs as novel activators of Multidrug Resistance-associated Protein 1 (MRP1, ABCC1).
Schmitt SM; Stefan K; Wiese M
Biochim Biophys Acta Biomembr; 2017 Jan; 1859(1):69-79. PubMed ID: 27810353
[TBL] [Abstract][Full Text] [Related]
24. Identification of 5,6-substituted 4-aminothieno[2,3-d]pyrimidines as LIMK1 inhibitors.
Sleebs BE; Nikolakopoulos G; Street IP; Falk H; Baell JB
Bioorg Med Chem Lett; 2011 Oct; 21(19):5992-4. PubMed ID: 21852129
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and Evaluation of Cytotoxic Activity of Some Pyrroles and Fused Pyrroles.
Fatahala SS; Mohamed MS; Youns M; Abd-El Hameed RH
Anticancer Agents Med Chem; 2017; 17(7):1014-1025. PubMed ID: 28042776
[TBL] [Abstract][Full Text] [Related]
26. Effects of pyrrolopyrimidine derivatives on cancer cells cultured in vitro and potential mechanism.
Kilic-Kurt Z; Celik A; Bakar-Ates F
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3169-3177. PubMed ID: 37891256
[TBL] [Abstract][Full Text] [Related]
27. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
[TBL] [Abstract][Full Text] [Related]
28. Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
Zhang JQ; Luo YJ; Xiong YS; Yu Y; Tu ZC; Long ZJ; Lai XJ; Chen HX; Luo Y; Weng J; Lu G
J Med Chem; 2016 Aug; 59(15):7268-74. PubMed ID: 27427973
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and evaluation of novel diaryl pyrrolopyrimidine and pyrrolothiazine derivatives as inhibitors of tumor necrosis factor stimulated gene-14 (TSG-14) production.
Hilmy KM; Soliman DH; Shahin EB; El-Deeb HS; El-Kousy SM
Eur J Med Chem; 2014 May; 78():419-24. PubMed ID: 24704614
[TBL] [Abstract][Full Text] [Related]
30. Pyrrolopyrimidine-inhibitors with hydantoin moiety as spacer can explore P4/S4 interaction on plasmin.
Teno N; Gohda K; Wanaka K; Tsuda Y; Sueda T; Yamashita Y; Otsubo T
Bioorg Med Chem; 2014 Apr; 22(7):2339-52. PubMed ID: 24613052
[TBL] [Abstract][Full Text] [Related]
31. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
Brasca MG; Nesi M; Avanzi N; Ballinari D; Bandiera T; Bertrand J; Bindi S; Canevari G; Carenzi D; Casero D; Ceriani L; Ciomei M; Cirla A; Colombo M; Cribioli S; Cristiani C; Della Vedova F; Fachin G; Fasolini M; Felder ER; Galvani A; Isacchi A; Mirizzi D; Motto I; Panzeri A; Pesenti E; Vianello P; Gnocchi P; Donati D
Bioorg Med Chem; 2014 Sep; 22(17):4998-5012. PubMed ID: 25009002
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P
Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675
[TBL] [Abstract][Full Text] [Related]
33. Novel antiviral compounds against gastroenteric viral infections.
Mohamed MS; Abd El-Hameed RH; Sayed AI; Soror SH
Arch Pharm (Weinheim); 2015 Mar; 348(3):194-205. PubMed ID: 25704120
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7.
Abdelhaleem EF; Abdelhameid MK; Kassab AE; Kandeel MM
Eur J Med Chem; 2018 Jan; 143():1807-1825. PubMed ID: 29133058
[TBL] [Abstract][Full Text] [Related]
35. Pyrrolizines: Promising scaffolds for anticancer drugs.
Belal A; El-Gendy Bel-D
Bioorg Med Chem; 2014 Jan; 22(1):46-53. PubMed ID: 24331756
[TBL] [Abstract][Full Text] [Related]
36. Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors.
Liu Y; Yin Y; Zhang J; Nomie K; Zhang L; Yang D; Wang ML; Zhao G
Arch Pharm (Weinheim); 2016 May; 349(5):356-62. PubMed ID: 26991997
[TBL] [Abstract][Full Text] [Related]
37. In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib.
Sundby E; Han J; Kaspersen SJ; Hoff BH
Eur J Pharm Sci; 2015 Dec; 80():56-65. PubMed ID: 26296860
[TBL] [Abstract][Full Text] [Related]
38. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Schenone S; Brullo C; Musumeci F; Botta M
Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
[TBL] [Abstract][Full Text] [Related]
39. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity.
Tari LW; Trzoss M; Bensen DC; Li X; Chen Z; Lam T; Zhang J; Creighton CJ; Cunningham ML; Kwan B; Stidham M; Shaw KJ; Lightstone FC; Wong SE; Nguyen TB; Nix J; Finn J
Bioorg Med Chem Lett; 2013 Mar; 23(5):1529-36. PubMed ID: 23352267
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors.
Zhao Y; Zhang J; Zhuang R; He R; Xi J; Pan X; Shao Y; Pan J; Sun J; Cai Z; Liu S; Huang W; Lv X
Bioorg Med Chem; 2017 Jun; 25(12):3195-3205. PubMed ID: 28412159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
